New perspectives on macrolide antibiotics

International Journal of Antimicrobial Agents

Volumn 18, Issue SUPPL.1, 2001, Pages 93-97

  Pechere J C ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Atherosclerosis; Azithromycin; Cystic fibrosis; Helicobacter pylori; Macrolides; Malaria; Non gonoccoccal urethritis; Peptic ulcer; Shigellosis; Trachoma; Typhoid

Indexed keywords

ANTIINFECTIVE AGENT; MACROLIDE;

ARTERIOSCLEROSIS; BRONCHIOLITIS; CYSTIC FIBROSIS; HUMAN; MALARIA; PEPTIC ULCER; REVIEW; TRACHOMA; URETHRITIS;

ANTI-BACTERIAL AGENTS; ARTERIOSCLEROSIS; BRONCHIOLITIS; CYSTIC FIBROSIS; HUMANS; MACROLIDES; MALARIA; PEPTIC ULCER; TRACHOMA; URETHRITIS;

EID: 0010977811     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0924-8579(01)00393-4     Document Type: Review

References (49)

1. Lister PJ, Balechandran T, Ridgway GL, Robinson AJ. Comparison of azithromycin and doxycycline in the treatment of non-gonococcal urethritis in men. J Antimicrob Chemother 1993;31(Suppl. E):185-92.
2. Lauharanta J, Saarinen K, Mustonen MT, Happonen HP. Single-dose oral azithromycin versus 7-day doxycycline in the treatment of non-gonococcal urethritis in males. J Antimicrob Chemother 1993;31(Suppl. E):177-83.
3. Nilsen A, Halsos A, Johansen A, et al. A double blind study of single dose azithromycin and doxycycline in the treatment of chlamydial urethritis in males. Genitourin Med 1992;68:325-7.
4. Martin DH, Mroczkowski TF, Dalu ZA, et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. N Engl J Med 1992;327:921-5.
5. Bailey RL, Arullendran P, Whittle HC, Mabey DC. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 1993;342:453-6.
6. Tabbara KF, Abu-el-Asrar A, al-Omar O, Choudhury AH, al-Faisal Z. Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology 1996;103:842-6.
7. Dawson CR, Schachter J, Sallam S, Sheta A, Rubinstein RA, Washton H. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clin Infect Dis 1997;24:363-8.
8. Bailey R, Lietman T. The SAFE strategy for the elimination of trachoma by 2020: will it work. Bull World Health Organ 2001;79:233-6.
9. Nieto FJ, Folsom AR, Sorlie PD, Grayston JT, Wang SP, Chambless LE. Chlamydia pneumonias infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 1999;150:149-56.
10. Yamashita K, Ouchi K, Shirai M, Gondo T, Nakazawa T, Ito H. Distribution of Chlamydia pneumoniae infection in the athersclerotic carotid artery. Stroke 1998;29:773-8.
11. Maass M, Jahn J, Gieffers J, Dalhoff K, Katus HA, Solbach W. Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction. J Infect Dis 2000;181(Suppl. 3):S449-51.
12. Laitinen K, Laurila A, Pyhala L, Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 1997;65:4832-5.
13. Fong IW. Antibiotics effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis. J Infect Dis 2000;181(Suppl. 3):S514-8.
14. Taylor-Robinson D, Thomas BJ. Chlamydia pneumoniae in atherosclerotic tissue. J Infect Dis 2000;181(Suppl. 3):S437-40.
15. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction. J Am Med Assoc 1999;281:427-31.
16. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. ROXIS Study Group, Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. Lancet 1997;350:404-7.
17. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
18. Dhaenens L, Szczebara F, Husson MO. In vitro activities of clarithromycin and other antimicrobial agents against Helicobacter pylori isolated from children. J Antimicrob Chemother 1996;38:318-9.
19. Logan RP, Gummett PA, Schaufelberger HD, et al. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 1994;35:323-6.
20. Graham DY. Clarithromycin for treatment of Helicobacter pylori infections. Eur J Gastroenterol Hepatol 1995;7(Suppl. 1):S55-8.
21. Uemura N, Okamoto S, Mukai T, et al. Effect of Helicobacter pylori eradication on the healing and recurrence of peptic ulcer: combination therapy with low-dose omeprazole and clarithromycin. Eur J Gastroenterol Hepatol 1995;7(Suppl. 1):S67-9.
22. Talley NJ, Vakil N, Ballard ED Jr, Fennerty MB. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999;341:1106-11.
23. Lehmann FS, Drewe J, Terracciano L, Beglinger C. Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 2000;14:305-9.
24. Gordillo ME, Singh KV, Murray BE. In vitro activity of azithromycin against bacterial enteric pathogens. Antimicrob Agents Chemother 1993;37:1203-5.
25. Gundert-Renny U, Christ W, Kemmler H. Biliary excretion of antimicrobial agents. Prog Pharm Clin Pharmacol 1991;8:323-54.
26. Gladue RP, Snider ME. Intracellular accumulation of azithromycin by cultural human fibroblasts. Antimicrob Agents Chemother 1990;34:1056-60.
27. Khan WA, Seas C, Dhar U, Salam MA, Bennish ML. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann Intern Med 1997;126:697-703.
28. Girgis NI, Butler T, Frenck RW, et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob Agents Chemother 1999;43:1441-4.
29. Fujii T, Kadota J, Kawakami K, et al. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995;50:1246-52.
30. Anderson JL, Muhlestein JB. The ACADEMIC study in perspective (azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia). J Infect Dis 2000;181(Suppl. 3):S569-71.
31. Kohri K, Tamaoki J, Kondo M, Aoshiba K, Tagaya E, Nagai A. Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages. Eur Respir J 2000;15:62-7.
32. Tateda K, Furuya N, Hirakata Y, et al. Effect of macrolide antibiotics on human serum-bactericidal sensitivity of Pseudomonas aeruginosa S-6. Kansenshogaku Zasshi 1991;65:1337-43.
33. Tateda K, Ishii Y, Matsumoto T, et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother 1996;40:2271-5.
34. Kita E, Sawaki M, Oku D, et al. Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin. J Antimicrob Chemother 1991;27:273-84.
35. Molinari G, Guzman CA, Pesce A, Schito GC. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 1993;31:681-8.
36. Mizukane R, Hirakata Y, Kaku M, et al. Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994;38:528-33.
37. Ozeki M, Miyamoto N, Hashiba M, Baba S. Inhibitory effect of roxithromycin on biofilm formation of Pseudomonas aeruginosa. Acta Otolaryngol Suppl 1996;525:61-3.
38. Kondoh K, Hashiba M, Baba S. Inhibitory activity of clarithromycin on biofilm synthesis with Pseudomonas aeruginosa. Acta Otolaryngol Suppl 1996;525:56-60.
39. Ichimiya T, Takeoka K, Hiramatsu K, Hirai K, Yamasaki T, Nasu M. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 1996;42:186-91.
40. Takeoka K, Ichimiya T, Yamasaki T, Nasu M. The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm. Chemotherapy 1998;44:190-7.
41. Nicolau DP, Banevicius MA, Nightingale CH, Quintiliani R. Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model. Antimicrob Agents Chemother 1999;43:3033-5.
42. Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2000;3:CD002203.
43. Gingras BA, Jensen JB. Activity of azithromycin (CP-62993) and erythromycin against chloroquine-sensitive and chloroquineresistant strains of Plasmodium falciparum in vitro. Am J Trop Med Hyg 1992;47:378-82.
44. Andersen SL, Ager A, McGreevy P, et al. Activity of azithromycin as a blood schizonticide against rodent and human plasmodia in vivo. Am J Trop Med Hyg 1995;52:159-61.
45. Sadiq ST, Glasgow KW, Drakeley CJ, et al. Effects of azithromycin on malariometric indices in The Gambia. Lancet 1995;346:881-2.
46. Roblin PM, Montalban G, Hammerschlag MR. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob Agents Chemother 1994;38:1588-9.
47. Roblin PM, Hammerschlag MR. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrob Agents Chemother 1998;42:146-94.
48. Megraud F. Resistance of Helicobacter pylori to antibiotics: the main limitation of current proton-pump inhibitor triple therapy. Eur J Gastroenterol Hepatol 1999;11(Suppl. 2):S35-7.
49. Bazzoli F, Berretti D, De Luca L, et al. What can be learnt from the new data about antibiotic resistance? Are there any practical clinical consequences of Helicobacter pylori antibiotic resistance. Eur J Gastroenterol Hepatol 1999;11(Suppl. 2):S39-42.